Advanced Cancer Therapeutics (ACT) is leading innovation within the biotechnology industry. Founded in January 2007, the company is focused on the discovery and early development of novel cancer therapeutics as well as selection for partnership, commercialization and manufacture of the most promising discoveries. Utilizing its groundbreaking business arrangement with the James Graham Brown Cancer Center and the University of Louisville Research Foundation, ACT will establish exclusive rights to specific novel therapeutics and fast-track these leading edge discoveries to the pharmaceutical industry, and ultimately the patients who need them.

ALFAMA is a young pharmaceutical company dedicated to the development of small-molecule drugs for unmet medical needs. ALFAMA's carbon monoxide releasing molecules (CORMs) hold the promise of contributing decisively to the prevention and cure of diseases involving inflammatory, infectious, thrombotic and apoptotic processes. Animal data indicates that various CORMs can be effective against ailments such as acute liver failure, multiple sclerosis, rheumatoid arthritis, transplant rejection, myocardial infarction, stroke, NSAID-induced gastric ulcers, hypertension and infection by antibiotic-resistant strains of bacteria. The core of ALFAMA's science is developed at state-of-the-art research facilities in the metropolitan areas of Lisbon (Portugal), where the company originally started, and Boston (Massachusetts, USA), where the headquarters of the mother company Alfama, Inc. are located.

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease. This research and development focus offers tremendous potential to identify novel, high-value therapies addressing a wide range of diseases and disorders triggered by inflammation, including asthma and cardiovascular disease. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Amira’s research strategy emphasizes systematic and early evaluation of compounds’ pharmacokinetics, pharmacodynamics and safety, leading to definitive “go-no go” decisions. The efficiency of this research process is enhanced by the discovery team’s unparalleled insights into bioactive lipid pathways and the complex signaling processes that control inflammation.

Anacor Pharmaceuticals is a biopharmaceutical company developing novel small-molecule therapeutics derived from its boron chemistry platform to treat infectious and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. Anacor also has a portfolio of other topical product candidates in development for the treatment of psoriasis, atopic dermatitis and skin and nail fungal infections. The company has entered into a worldwide license, development and commercialization agreement with Merck for the development and commercialization of AN2690 for all indications including the treatment of onychomycosis. In addition, Anacor has a research and development agreement with GSK for novel antiviral and antibacterial systemic therapeutics.

Ardea, headquartered in San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer, inflammatory diseases and human immunodeficiency virus (HIV). Ardea was formerly known as IntraBiotics Pharmaceuticals, Inc. and was incorporated in the State of Delaware in 1994. In December 2006, we acquired intellectual property and other assets related to three distinct pharmaceutical research and development programs from Valeant Research & Development, Inc., or Valeant.  Since that time, we have successfully advanced all of these programs and expanded beyond them to establish our current pipeline of product candidates.